Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression.
Alison R WalkerJohn C ByrdJames S BlachlyBhavana BhatnagarAlice S MimsShelley OrwickTara L LinHowland E CrosswellDanjie ZhangMark D MindenVeerendra MunugalavadlaLauren LongJinfeng LiuYang PanThomas OellerichHubert ServeArati V RaoWilliam G BlumPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Entospletinib with intensive chemotherapy was well-tolerated in patients with AML. Improved survival was observed in patients with HOXA9/MEIS1 overexpression, contrasting published data demonstrating poor survival in such patients. A randomized study will be necessary to determine whether entospletinib was a mediator this observation.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- long non coding rna
- ejection fraction
- poor prognosis
- chronic kidney disease
- locally advanced
- allogeneic hematopoietic stem cell transplantation
- long noncoding rna
- prognostic factors
- squamous cell carcinoma
- free survival
- electronic health record
- randomized controlled trial
- radiation therapy
- machine learning
- patient reported outcomes
- rectal cancer
- deep learning